Xcellon Biologics, a Maryland-based contract research, development, and manufacturing organization (CRDMO), has agreed to acquire a GMP biologics manufacturing facility from NextCure, expanding its capabilities for bioconjugates and complex biologics. Terms of the acquisition were not disclosed.

The 40,000-square-foot facility includes two 1,000-liter single-use bioreactors, a dedicated bioconjugation suite, process development capabilities using robotics, as well as analytical and characterization laboratories. Xcellon said the acquisition will integrate these manufacturing capabilities with its existing bioconjugation development expertise.

The facility is expected to begin Good Manufacturing Practice (GMP) operations in December 2026. Once operational, Xcellon plans to support programs spanning discovery, development, GMP manufacturing, and clinical supply through a single CRDMO.

The acquisition follows Xcellon’s launch in 2025 and expands its services for biotechnology companies developing antibody-based therapeutics and other complex biologics. The company said integrating antibody development, bioconjugation, analytical sciences, and GMP manufacturing is intended to reduce handoffs between service providers and maintain continuity through development.

As part of the expansion, Xcellon co-founder Abhishake Chhibber has been named chief executive officer. He will lead the company’s strategy and operations as it expands its CRDMO platform.